The INO-4800 vaccine is currently being tested in the U.S. through a phase I clinical trial. If proved safe, it could advance to phase II and III clinical trials later this year. Meanwhile, Richter-Helm BioLogics will transfer and rapidly scale up production processes for the INO-4800 DNA plasmid using its VGXI manufacturing technology.

The manufacturing partnership, which aims to produce 1 million doses of INO-4800 in 2020, is partly funded through a $1.3 million grant from the Coalition for Epidemic Preparedness Innovations (CEPI). Inovio also partners with Richter-Helm BioLogics for its DNA medicine candidate VGX-3100 for the potential treatment of HPV-related precancerous cervical dysplasia.

COVID-19: A double-edged sword for the pharma industry
The COVID-19 pandemic is causing major disruptions to pharmaceutical R&D activities, despite the pressing need for treatments and diagnostics for the...

CEPI, Clover to partner on COVID-19 vaccine
The Coalition for Epidemic Preparedness Innovations (CEPI) and Clover Biopharmaceuticals Australia plan to partner on the development of a COVID-19 vaccine.

COVID-19 vaccine candidates show progress amid challenges
As the COVID-19 outbreak advances worldwide, companies are stepping up to the challenge to develop a potential vaccine. There are over 75 confirmed COVID-19...